

# Eleni Bekiari

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2382702/eleni-bekiari-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49 papers	1,459 citations	14 h-index	38 g-index
52 ext. papers	1,926 ext. citations	5.5 avg, IF	4.67 L-index

#	Paper	IF	Citations
49	Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 106-114	6.7	2
48	KDIGO made 12 recommendations for managing diabetes with CKD. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, JC26	8	
47	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 174, 108737	7.4	12
46	Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2116-2124	6.7	9
45	Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2395-2401	6.7	1
44	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 177, 108921	7.4	3
43	Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 822-831	6.7	6
42	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 141	8	
41	Add-on interventions for the prevention of recurrent <i>Clostridioides Difficile</i> infection: A systematic review and network meta-analysis. <i>Anaerobe</i> , <b>2021</b> , 71, 102441	2.8	0
40	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases.. <i>Journal of Inflammation Research</i> , <b>2021</b> , 14, 6893-6906	4.8	1
39	Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1857-1868	6.7	14
38	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 335-345	6.7	27
37	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. <i>Journal of General Internal Medicine</i> , <b>2020</b> , 1	4	5
36	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 278-286	8	70
35	Some glucose-lowering drugs reduce risk for major adverse cardiac events. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, JC9	8	1
34	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, JC70	8	
33	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2019</b> , 34, 281-289	2.5	5

32	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 188-193	6.7	20
31	Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1744-1755.e11	6.9	49
30	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2019</b> , 12, 2549-2557	3.4	4
29	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2018</b> , 361, k1310	5.9	192
28	In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, JC46	8	
27	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2018</b> , 169, 165-174	8	27
26	Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 595-602	3.4	10
25	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 572-582	2.2	17
24	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2255-2263	6.7	39
23	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. <i>European Journal of Haematology</i> , <b>2017</b> , 98, 563-568	3.8	6
22	Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. <i>Endocrine</i> , <b>2017</b> , 56, 485-494	4	11
21	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 843-851	4	14
20	Meta-analysis of artificial pancreas trials: methodological considerations. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 685	18.1	2
19	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , <b>2017</b> , 37, 293-298	3.6	14
18	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. <i>Core Evidence</i> , <b>2017</b> , 12, 1-10	4.9	5
17	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. <i>Endocrine</i> , <b>2016</b> , 54, 620-633	4	4
16	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. <i>Endocrine</i> , <b>2016</b> , 52, 458-80	4	34
15	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. <i>Therapeutic Advances in Drug Safety</i> , <b>2016</b> , 7, 36-8	3.5	12

14	Most add-on therapies to metformin have similar effects on HbA1c. <i>Evidence-Based Medicine</i> , <b>2016</b> , 21, 223		
13	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , <b>2016</b> , 10, 1	0.9	
12	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. <i>Diabetes Management</i> , <b>2015</b> , 5, 119-125	2	
11	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2015</b> , 6, 61-7	4.5	24
10	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 241	8	1
9	A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 584-92	12.7	24
8	Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , <b>2013</b> , 159, 262-74	8	596
7	Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients. <i>Hemoglobin</i> , <b>2013</b> , 37, 94-100	0.6	5
6	Erythrocytosis Secondary to Testosterone Therapy in a Male with Cryptorchidism: A Case Report. <i>International Journal of Gerontology</i> , <b>2012</b> , 6, 290-291		1
5	Effect of epinephrine and insulin resistance on human monocytes obtained from lean and obese healthy participants: a pilot study. <i>Angiology</i> , <b>2011</b> , 62, 38-45	2.1	7
4	Effect of glucose and insulin on oxidized low-density lipoprotein phagocytosis by human monocytes: a pilot study. <i>Angiology</i> , <b>2011</b> , 62, 163-6	2.1	4
3	Eosinophilic pneumonia associated with heroin inhalation: a case report. <i>Wiener Klinische Wochenschrift</i> , <b>2008</b> , 120, 178-80	2.3	10
2	Insulin sensitivity assessment with euglycemic insulin clamp in adult beta-thalassaemia major patients. <i>European Journal of Haematology</i> , <b>2007</b> , 79, 526-30	3.8	8
1	Hemosiderosis and diabetes mellitus in an untransfused patient with hemoglobin H disease and H63D homozygous hereditary hemochromatosis. <i>Diabetes Research and Clinical Practice</i> , <b>2007</b> , 76, 468-9	7.4	